New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
08:58 EDTOMER, MRK, RL, COCO, DATA, XONE, DDD, CTSH, VJET, SSYSOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Merck (MRK), up 1.6%... Ralph Lauren (RL), up 7%... Tableau Software (DATA), up 12%... Corinthian Colleges (COCO), up 2%. ALSO HIGHER: Omeros (OMER), up 11% after granted fast track designation to OMS824 by FDA. DOWN AFTER EARNINGS: Allergan (AGN), down xx%... Cognizant (CTSH), down 5%. ALSO LOWER: 3D Systems (DDD), down 15% after lowering FY13 EPS view, guiding FY14 below estimates. Peers Stratasys (SSYS), down 7.5%, ExOne (XONE), down 8%, and Voxeljet (VJET), down 7%, lower as well.
News For DDD;RL;SSYS;XONE;MRK;VJET;DATA;OMER;CTSH;COCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 7, 2015
07:08 EDTMRKAllergan to acquire rights to Merck's CGRP for $250M
Subscribe for More Information
July 6, 2015
10:01 EDTCTSHOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: 58.com (WUBA) upgraded to Buy from Hold at Summit Research... Altria Group (MO) upgraded to Buy from Outperform at CLSA... Ares Commercial (ACRE) upgraded to Outperform from Market Perform at FBR Capital... BAE Systems (BAESY) upgraded to Overweight from Equal Weight at Morgan Stanley... BGC Partners (BGCP) upgraded to Strong Buy from Outperform at Raymond James... Cognizant (CTSH) upgraded to Buy on valuation at CLSA... Edwards Lifesciences (EW) upgraded to Overweight from Equal Weight at Morgan Stanley... Guess (GES) upgraded to Neutral from Underweight at Piper Jaffray... MarkWest Energy (MWE) upgraded to Overweight from Equal Weight at Barclays... Palo Alto (PANW) upgraded to Outperform following checks at Cowen... The Medicines Co. (MDCO) upgraded to Buy from Neutral at Mizuho... TripAdvisor (TRIP) upgraded to Equal Weight from Underweight at Barclays... Union Pacific (UNP) upgraded to Outperform at Cowen... United Continental (UAL) upgraded to Buy from Fair Value at CRT Capital... eHealth (EHTH) upgraded on Medicare outlook, risk/reward at RBC Capital.
09:07 EDTXONEExOne management to meet with Oppenheimer
Meetings to be held in Milwaukee/St. Louis on July 7 hosted by Oppenheimer.
08:18 EDTCTSHCognizant upgraded to Buy on valuation at CLSA
As previously reported, CLSA upgraded Cognizant to Buy from Outperform with a $75 price target. The firm would use weakness as a buying opportunity and said the loss of the Health Net (HNT) contract was very sub-par margin revenue.
07:58 EDTOMEROmeros weakness creates buying opportunity, says Wedbush
After Omeros' stock sank about 23% since June 22, Wedbush notes that on June 25 an article recommended selling Omeros' stock. The firm says that the article based its conclusion on financial parameters suited to a mature, profitable company, rather than one which just launched its first drug, as is the case with Omeros. Wedbush adds that if the selloff in the stock was caused by the article, it recommends buying the shares. It believes that Omeros' fundamentals haven't changed, while the company has potentially significant catalysts this year. Wedbush keeps an Outperform rating on Omeros.
06:17 EDTCTSH, CTSHCognizant upgraded to Buy from Outperform at CLSA
July 2, 2015
12:00 EDTCTSHCognizant ability to offset Health Net loss a positive, says Wells Fargo
Wells Fargo notes that despite the loss of $100M in revenue in the second half of 2015 from the Health Net (HNT) master services agreement being put on hold during the Centene (CNC) merger review process, Cognizant (CTSH) reaffirmed its outlook today for 2015. Wells views the company's ability to offset the contract loss as a positive and says it remains comfortable with an Outperform rating on the stock.
09:36 EDTCTSHCognizant backs FY15 EPS view of at least $2.93, consensus $2.97
Subscribe for More Information
09:33 EDTCTSHCognizant reaffirms 2015 view after Health Net agrees to be bought by Centene
Subscribe for More Information
08:06 EDTSSYSStratasys acquires RTC Rapid Technologies to strengthen presence in GSC region
Subscribe for More Information
June 29, 2015
08:39 EDTMRKMerck says Phase 3 Emend data shows it provides 'greater protection' from nausea
Merck announced results from a Phase 3 study investigating the safety and efficacy of single-dose Emend for Injection, Merck’s substance P/neurokinin receptor antagonist, in combination with other anti-vomiting medicines, for the prevention of chemotherapy-induced nausea and vomiting, or CINV, in adult cancer patients receiving moderately emetogenic chemotherapy, or MEC. In the study, the first to evaluate an intravenous NK-1 receptor antagonist for the prevention of CINV associated with MEC, the single-dose Emend for Injection regimen provided greater protection from nausea and vomiting following administration of chemotherapy versus an active control of placebo with other anti-vomiting medicines. These data were presented in an oral session at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on “Supportive Care in Cancer” in Copenhagen.
June 25, 2015
09:10 EDTDDD3D Systems partners with MLC CAD Systems
Subscribe for More Information
June 24, 2015
09:07 EDTMRKCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
05:47 EDTDDDStocks with implied volatility movement; NRF DDD
Subscribe for More Information
05:35 EDTCTSHCognizant announces strategic relationship with Escorts Limited
Cognizant announced a strategic relationship with Escorts Limited, one of India's engineering conglomerates, to modernize Escorts' technology landscape and help achieve the company's vision of digitally transforming its businesses to deliver innovative products, provide superior customer experience, and drive growth. This multi-year, multi-million dollar engagement spans all of Escort's businesses, including agri-machinery, material handling and construction equipment, railway equipment and auto components. Cognizant will enable Escorts to improve control and collaboration across its value chain by mobile-enabling its workforce and integrating multiple systems used by vendors, sales partners, and customers. This will help Escorts continuously improve product quality and offer a broad range of customized, configurable, and value-added products and services, strengthening existing customer relationships and building new ones.
June 23, 2015
12:03 EDTDDD3D Systems volatility at low end of historic range
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use